ES2160897T3 - Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica. - Google Patents

Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.

Info

Publication number
ES2160897T3
ES2160897T3 ES97309701T ES97309701T ES2160897T3 ES 2160897 T3 ES2160897 T3 ES 2160897T3 ES 97309701 T ES97309701 T ES 97309701T ES 97309701 T ES97309701 T ES 97309701T ES 2160897 T3 ES2160897 T3 ES 2160897T3
Authority
ES
Spain
Prior art keywords
pirazoles
secretora
phosfolipasa
pancreatica
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97309701T
Other languages
English (en)
Inventor
Peter Jeremy Doman
Gary Alan Hite
Edward David Mihelich
Tulio Suarez
Stuart Edmund Willetts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2160897T3 publication Critical patent/ES2160897T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCUBRE UNA CLASE DE NUEVOS PIRAZOLES JUNTO CON EL USO DE DICHOS COMPUESTOS PARA LA INHIBICION DE LA LIBERACION MEDIADA POR PLA{SUB,2} DE ACIDOS GRASOS PARA EL TRATAMIENTO DE ESTADOS TALES COMO EL CHOQUE SEPTICO.
ES97309701T 1996-12-04 1997-12-02 Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica. Expired - Lifetime ES2160897T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3321696P 1996-12-04 1996-12-04

Publications (1)

Publication Number Publication Date
ES2160897T3 true ES2160897T3 (es) 2001-11-16

Family

ID=21869147

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97309701T Expired - Lifetime ES2160897T3 (es) 1996-12-04 1997-12-02 Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.

Country Status (22)

Country Link
US (1) US5972972A (es)
EP (1) EP0846687B1 (es)
JP (1) JP2002515053A (es)
KR (1) KR20000057366A (es)
AR (1) AR010743A1 (es)
AT (1) ATE203985T1 (es)
AU (1) AU5365598A (es)
BR (1) BR9713993A (es)
CA (1) CA2274048A1 (es)
CO (1) CO4910169A1 (es)
DE (1) DE69706027T2 (es)
DK (1) DK0846687T3 (es)
ES (1) ES2160897T3 (es)
HK (1) HK1011865A1 (es)
HU (1) HUP0000292A3 (es)
ID (1) ID18983A (es)
IL (1) IL130202A0 (es)
PE (1) PE20599A1 (es)
PT (1) PT846687E (es)
TW (1) TW432051B (es)
WO (1) WO1998024437A1 (es)
ZA (1) ZA9710878B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
EP1019394A1 (en) 1997-05-22 2000-07-19 G.D. Searle & Co. PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
HUP0102981A3 (en) 1998-03-31 2002-10-28 Shionogi & Co Pyrrolo[1,2-a]pyrazine derivatives and pharmaceutical compositions thereof
AU748787B2 (en) 1998-05-21 2002-06-13 Shionogi & Co., Ltd. Pyrrolo(1,2-b)pyridazine derivatives having sPLA2 inhibitory effect
EP1157704B1 (en) 1998-10-14 2006-06-14 Shionogi & Co., Ltd. Spla2 inhibitors for the treatment of ischaemic reperfusion injury
US6703385B1 (en) 1999-07-19 2004-03-09 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
US6673781B1 (en) 1999-08-02 2004-01-06 Shionogi & Co., Ltd. Tricyclic compounds having sPLA2-inhibitory activities
US6787545B1 (en) 1999-08-23 2004-09-07 Shiongi & Co., Ltd. Pyrrolotriazine derivatives having spla2-inhibitory activities
ES2171116B1 (es) * 2000-04-14 2003-08-01 Esteve Quimica Sa Procedimiento para la obtencion de derivados de (((piridil sustituido)metil)tio)bencimidazol.
AU2001267825A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for cirrhosis
AU2001267823A1 (en) 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Compounds exhibiting x-type spla2 inhibiting effect
TWI314457B (es) 2001-03-19 2009-09-11 Shionogi & Co
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
US20040018533A1 (en) * 2002-06-04 2004-01-29 Adam Gail Isabel Reid Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003248793A1 (en) * 2002-06-27 2004-01-19 Sequenom, Inc Diagnosing predisposition to fat deposition and associated condition
WO2004002296A2 (en) * 2002-06-27 2004-01-08 Sequenom, Inc. Therapeutic methods for reducing fat deposition and treating associated conditions
BRPI0906577A2 (pt) * 2008-01-25 2019-09-24 Syngenta Partcipations Ag compostos químicos
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
CN105017134A (zh) * 2015-07-26 2015-11-04 陈吉美 一种4-吡啶丙烯酸的制备方法
SG11202006614VA (en) 2018-02-15 2020-08-28 Vertex Pharma Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
JP2022544383A (ja) 2019-08-14 2022-10-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒモジュレータの結晶形態
TW202120517A (zh) 2019-08-14 2021-06-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TW202115092A (zh) 2019-08-14 2021-04-16 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
WO2022076628A1 (en) * 2020-10-07 2022-04-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3616681A1 (de) * 1986-05-16 1987-11-19 Bayer Ag 1-aralkylpyrazole
JPH02229169A (ja) * 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
JPH02229168A (ja) * 1989-03-01 1990-09-11 Takeda Chem Ind Ltd ピラゾロン誘導体
ATE157969T1 (de) * 1990-07-10 1997-09-15 Ishihara Sangyo Kaisha Diaminotrifluoromethylpyrimidinderivate, verfahren zu ihrer herstellung und diese enthaltende phospholipase-a2-inhibitoren
EP0539034A1 (en) * 1991-10-22 1993-04-28 Konica Corporation A novel photographic cyan coupler
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5500439A (en) * 1993-12-09 1996-03-19 Alteon Inc. Aminopyrazoles
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
CA2274048A1 (en) 1998-06-11
US5972972A (en) 1999-10-26
CO4910169A1 (es) 2000-04-24
BR9713993A (pt) 2000-02-08
AR010743A1 (es) 2000-07-12
IL130202A0 (en) 2000-06-01
TW432051B (en) 2001-05-01
WO1998024437A1 (en) 1998-06-11
DK0846687T3 (da) 2001-10-08
PT846687E (pt) 2001-12-28
ID18983A (id) 1998-05-28
ZA9710878B (en) 1999-06-03
JP2002515053A (ja) 2002-05-21
DE69706027T2 (de) 2002-03-14
EP0846687B1 (en) 2001-08-08
ATE203985T1 (de) 2001-08-15
KR20000057366A (ko) 2000-09-15
HUP0000292A2 (hu) 2001-04-28
DE69706027D1 (de) 2001-09-13
AU5365598A (en) 1998-06-29
PE20599A1 (es) 1999-03-05
HK1011865A1 (en) 1999-07-23
HUP0000292A3 (en) 2002-01-28
EP0846687A1 (en) 1998-06-10

Similar Documents

Publication Publication Date Title
ES2160897T3 (es) Pirazoles como inhibidores de la secretora fosfolipasa a2 humana no pancreatica.
ES2179088T3 (es) Inhibidores de flsa2 1h-indol-3-glioxilamida.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
EA199900301A2 (ru) Замещенные трициклические соединения
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
GT199900056A (es) Nuevas dihidropirimidinas
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
NO991557D0 (no) Anvendelse av alkansulfonsyrer som asfalten-dispergeringsmidler
UY24006A1 (es) Derivado del 2-(2-amino -1,6-dihidro-6-oxo-purin-9-il)metoxil-1,3-propanodiol.
ES2221950T3 (es) Dihidrobenzofurano y compuestos relacionados utiles como agentes anti-inflamatorios.
ES2013631B3 (es) Metodo para el tratamiento de tejidos.
EA199900304A2 (ru) Замещенные трициклические соединения
UY25356A1 (es) Polisacaridos de sintesis,procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR9713370A (pt) Processos para fabricação de metoprolol e de uma preparação farmacêutica, e, metoprolol
ID17291A (id) Penghambat matriks metalloprotease oleh asam biaril oksobutirat tersubstitusi
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
SE9801494D0 (sv) Novel use
ES2195182T3 (es) Fenil glioxamidas como inhibidores de spla2.
ECSP003590A (es) Compuestos calcioliticos
ES2174034T3 (es) Naftilglioxamidas como inhibidores de spla2
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
ES2180175T3 (es) Uso de una sustancia inhibidora para la mejora de la regeneracion neuronal.
ATE247119T1 (de) Substituierte pyrroloindole

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 846687

Country of ref document: ES